These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 31506382)

  • 1. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
    Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D
    Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
    Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
    Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
    Meng X; Jing R; Qian L; Zhou C; Sun J
    Front Immunol; 2020; 11():1046. PubMed ID: 32636832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
    Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
    Front Immunol; 2018; 9():1062. PubMed ID: 29899740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of CAR-Mediated Tonic Signaling.
    Calderon H; Mamonkin M; Guedan S
    Methods Mol Biol; 2020; 2086():223-236. PubMed ID: 31707680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunoproteomic approach to characterize the CAR interactome and signalosome.
    Ramello MC; Benzaïd I; Kuenzi BM; Lienlaf-Moreno M; Kandell WM; Santiago DN; Pabón-Saldaña M; Darville L; Fang B; Rix U; Yoder S; Berglund A; Koomen JM; Haura EB; Abate-Daga D
    Sci Signal; 2019 Feb; 12(568):. PubMed ID: 30755478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function.
    Salzer B; Schueller CM; Zajc CU; Peters T; Schoeber MA; Kovacic B; Buri MC; Lobner E; Dushek O; Huppa JB; Obinger C; Putz EM; Holter W; Traxlmayr MW; Lehner M
    Nat Commun; 2020 Aug; 11(1):4166. PubMed ID: 32820173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The making and function of CAR cells.
    Zabel M; Tauber PA; Pickl WF
    Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.
    Gallego-Valle J; Pérez-Fernández VA; Rosales-Magallares J; Gil-Manso S; Castellá M; Gonzalez-Navarro EA; Correa-Rocha R; Juan M; Pion M
    Front Immunol; 2024; 15():1448752. PubMed ID: 39364400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain.
    Vorri SC; Holl NJ; Leeming M; Apostolova P; Marple A; Ravich JW; Canbaz A; Rahnama R; Choe J; Modi A; Fearnow AD; Walsh STR; Pearce EL; Varadhan R; Bonifant CL
    Cancer Res Commun; 2024 Sep; 4(9):2359-2373. PubMed ID: 39186002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.
    Nunoya JI; Imuta N; Masuda M
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.